عرض بسيط للتسجيلة

المؤلفYounes, Salma
المؤلفNicolai, Eleonora
المؤلفPieri, Massimo
المؤلفBernardini, Sergio
المؤلفDaas, Hanin I
المؤلفAl-Sadeq, Duaa W
المؤلفYounes, Nadin
المؤلفShurrab, Farah M
المؤلفNizamuddin, Parveen B
المؤلفHumaira, Fathima
المؤلفAl-Dewik, Nader
المؤلفYassine, Hadi M
المؤلفAbu-Raddad, Laith J
المؤلفIsmail, Ahmed
المؤلفNasrallah, Gheyath K
تاريخ الإتاحة2024-05-26T04:23:12Z
تاريخ النشر2024-05-01
اسم المنشورInfluenza and other Respiratory Viruses
المعرّفhttp://dx.doi.org/10.1111/irv.13290
الاقتباسYounes, S., Nicolai, E., Pieri, M., Bernardini, S., Daas, H., Al-Sadeq, D., Younes, N., Shurrab, F., Nizamuddin, P., Humaira, F., Al-Dewik, N., Yassine, H., Abu-Raddad, L., Ismail, A. and Nasrallah, G. (2024), Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination. Influenza Other Respi Viruses, 18: e13290. https://doi.org/10.1111/irv.13290
الرقم المعياري الدولي للكتاب17502640
معرّف المصادر الموحدhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85192110589&origin=inward
معرّف المصادر الموحدhttp://hdl.handle.net/10576/55349
الملخصBackground: Priming with ChAdOx1 followed by heterologous boosting is considered in several countries. Nevertheless, analyses comparing the immunogenicity of heterologous booster to homologous primary vaccination regimens and natural infection are lacking. In this study, we aimed to conduct a comparative assessment of the immunogenicity between homologous primary vaccination regimens and heterologous prime-boost vaccination using BNT162b2 or mRNA-1273. Methods: We matched vaccinated naïve (VN) individuals (n = 673) with partial vaccination (n = 64), primary vaccination (n = 590), and primary series plus mRNA vaccine heterologous booster (n = 19) with unvaccinated naturally infected (NI) individuals with a documented primary SARS-CoV-2 infection (n = 206). We measured the levels of neutralizing total antibodies (NTAbs), total antibodies (TAbs), anti-S-RBD IgG, and anti-S1 IgA titers. Results: Homologous primary vaccination with ChAdOx1 not only showed less potent NTAb, TAb, anti-S-RBD IgG, and anti-S1 IgA immune responses compared to primary BNT162b2 or mRNA-1273 vaccination regimens (p < 0.05) but also showed ~3-fold less anti-S1 IgA response compared to infection-induced immunity (p < 0.001). Nevertheless, a heterologous booster led to an increase of ~12 times in the immune response when compared to two consecutive homologous ChAdOx1 immunizations. Furthermore, correlation analyses revealed that both anti-S-RBD IgG and anti-S1 IgA significantly contributed to virus neutralization among NI individuals, particularly in symptomatic and pauci-symptomatic individuals, whereas among VN individuals, anti-S-RBD IgG was the main contributor to virus neutralization. Conclusion: The results emphasize the potential benefit of using heterologous mRNA boosters to increase antibody levels and neutralizing capacity particularly in patients who received primary vaccination with ChAdOx1.
راعي المشروعGKN would like to acknowledge the funding from WHO grant number COVID-19-22-43 and Qatar University grant No. QUCG-BRC-23/24-170. This work was made possible by grant number UREP28-173-3-057 from the Qatar National Research Fund (a member of Qatar Foundation). The statements made herein are solely the responsibility of the authors.
اللغةen
الناشرWiley
الموضوعanti-S-RBD IgG
anti-S1-IgA
antibodies
booster
COVID-19
immune response
neutralizing antibody
vaccination
العنوانFollow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination
النوعArticle
رقم العدد5
رقم المجلد18
ESSN1750-2659
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة